Better Therapeutics, Inc.

OTCPK:BTTX Stock Report

Market Cap: US$5.5k

Better Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure3.2yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

Seeking Alpha • Sep 22

Better Therapeutics files for FDA approval of new type of digital therapy for diabetes

Better Therapeutics (NASDAQ:BTTX) said it filed a de novo classification request to the U.S. Food and Drug Administration (FDA) seeking approval of digital device BT-001 to use cognitive behavioral therapy (CBT) to treat type 2 diabetes (T2D) in patients 18 years and older. According to the FDA the De Novo request provides a marketing pathway to classify new medical devices for which there is no legally marketed predicate device. The submission included data from a trial which showed statistically and clinically meaningful reductions in A1c (blood sugar levels) over the current standard of care, even as control group patients increased use of blood sugar lowering drugs, the company said in a Sept. 22 press release. Better Therapeutics noted that if authorized, BT-001 would be the first validated, prescription solution for delivering CBT to patients with T2D at scale, from their digital devices. The investigational therapy is delivered via software which is aimed to help patients address the underlying causes of T2D by making sustainable behavioral changes, the company added. BTTX -1.06% to 1.87 premarket Sept. 22
Seeking Alpha • Aug 11

Better Therapeutics GAAP EPS of -$0.42 in-line

Better Therapeutics press release (NASDAQ:BTTX): Q2 GAAP EPS of -$0.42 in-line. Cash and cash equivalents were $29.7M on June 30, 2022, compared to $40.6M on December 31, 2021.
Seeking Alpha • May 12

Better Therapeutics: App-Based Therapeutics, Doesn't Look Novel

Better Therapeutics is delivering a cognitive behavioural therapy through a smartphone app. It is targeting traditionally biopharma diseases like diabetes and other cardiometabolic diseases. I am not convinced about how the company plans to address competition.
Seeking Alpha • Nov 30

Better Therapeutics: Pioneering Prescription Digital Therapeutics Platform For Cardiometabolic Diseases

Better Therapeutics has developed a proprietary platform for creating FDA-regulated, software-based solutions for cardiometabolic diseases. The Company is developing novel cognitive behavioral therapy to address the root causes of type 2 diabetes, heart disease and other conditions. The Company’s clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.

CEO

Better Therapeutics has no CEO, or we have no data on them.

Leadership Team

NamePositionTenureCompensationOwnership
David Perry
Co-Founder & Executive Chairman4.9yrsUS$119.25kno data
Frank Karbe
Interim CFO2.8yrsUS$557.50kno data
Mark Berman
Chief Medical Officer4.9yrsUS$593.70kno data
Kristin Wynholds
Chief Product Officer4.9yrsUS$558.70kno data
Andres Camacho
Senior VP of Technology & Head of Engineeringno datano datano data
Angela Willis
Senior Vice President of Market Access3.2yrsno datano data
Jessica Meng
Chief Commercial Officer2.6yrsno datano data
3.2yrs
Average Tenure
53yo
Average Age

Experienced Management: BTTX's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Perry
Co-Founder & Executive Chairman4.9yrsUS$119.25kno data
Andrew Armanino
Independent Director4.9yrsUS$36.09kno data
Richard Carmona
Independent Director4.9yrsUS$159.56kno data
Geoffrey Parker
Independent Director4.9yrsUS$36.34kno data
Elder Granger
Independent Director4.8yrsUS$32.34kno data
4.9yrs
Average Tenure
61yo
Average Age

Experienced Board: BTTX's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/21 20:37
End of Day Share Price 2026/09/18 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Better Therapeutics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Keay NakaeChardan Capital Markets, LLC
Thomas FlatenLake Street Capital Markets, LLC
Rahul RakhitLifeSci Capital, LLC